Inovio Pharmaceuticals appoints three vice presidents
Dr. Ildiko Csiki will serve Inovio as Vice President, Clinical Development, Oncology, responsible for advancing Inovio’s cancer programs.
Prior to joining Inovio, Dr. Csiki had been clinical lead and senior director of clinical research at Merck & Co. where she guided Merck’s global solid tumor development program and was lead for several registration studies.
Dr. Csiki also served as GSK’s director of clinical development and lead physician for the follicular lymphoma program.
She earned her MD and PhD degrees from Vanderbilt University School of Medicine and her BS in Biology and BA in Psychology from the University of Arkansas.
Dr. Jeffrey Skolnik, Vice President, Clinical Development, Oncology, will also direct Inovio’s cancer immunotherapy programs.
Dr. Skolnik was previously vice president of clinical research at TetraLogic Pharmaceuticals, where he oversaw all global clinical assets. He also served as a medical director at GSK and AstraZeneca.
Dr. Skolnik earned his MD at New York University, with honors in pathology, and his undergraduate degree from the University of Pennsylvania.
Robert J. Juba Jr. has been promoted to Vice President, Biological Manufacturing and Clinical Supply Management.
Mr. Juba Jr. has 22 years of experience in the pharmaceutical industry managing cGMP processes and operations, with extensive technical expertise in bacterial vaccine manufacturing.
He led plasmid manufacturing at VGXI and held several positions at Merck in bulk vaccine manufacturing operations and strategy.
Mr. Juba Jr. holds Masters and BS degrees in Chemical Engineering from the Massachusetts Institute of Technology.